Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
Sales Information [Line Items] | ||||||||||||
Total net margin | $ 121,653 | $ 162,197 | $ 152,933 | |||||||||
General & administrative | 65,147 | 53,391 | 64,481 | |||||||||
Research and development | 26,768 | 28,577 | 22,861 | |||||||||
Amortization of intangible assets | 2,687 | 2,298 | 2,550 | |||||||||
Costs related to the accounting review and restatement | 12,945 | |||||||||||
Impairment of goodwill | 19,193 | 19,193 | ||||||||||
Charges related to U.S. Government resolutions | 1,295 | 57,141 | ||||||||||
Operating (loss) income | 6,378 | (15,600) | 8,804 | 8,087 | 25,613 | 18,805 | 14,298 | 17,920 | (5,087) | 76,636 | 5,900 | |
BioStim [Member]
|
||||||||||||
Sales Information [Line Items] | ||||||||||||
Total net margin | 64,930 | 86,654 | 93,056 | |||||||||
Impairment of goodwill | ||||||||||||
Biologics [Member]
|
||||||||||||
Sales Information [Line Items] | ||||||||||||
Total net margin | 24,532 | 23,559 | 18,979 | |||||||||
Impairment of goodwill | ||||||||||||
Extremity Fixation [Member]
|
||||||||||||
Sales Information [Line Items] | ||||||||||||
Total net margin | 26,389 | 34,337 | 29,530 | |||||||||
Impairment of goodwill | 9,825 | |||||||||||
Spine Fixation [Member]
|
||||||||||||
Sales Information [Line Items] | ||||||||||||
Total net margin | 7,245 | 19,142 | 13,068 | |||||||||
Impairment of goodwill | 9,368 | |||||||||||
Corporate [Member]
|
||||||||||||
Sales Information [Line Items] | ||||||||||||
Total net margin | $ (1,443) | $ (1,495) | $ (1,700) |